Table 1.

Demographic and disease characteristics of the sample (n = 81). Values are expressed as mean (SD) unless stated otherwise.

CharacteristicValue
Age, yrs66.4 (10.5)
Male sex, n (%)65 (80.2)
Ethnicity, n (%)
  White79 (97.5)
  Asian2 (2.5)
Body mass index (kg/m2)29.4 (4.6)
Disease duration, yrs11.1 (10.0)
No. gout flares last year, median (IQR)1 (0–3)
  Last flare in foot/ankle, n (%)70 (86.4)
Currently taking ULT, n (%)57 (70.4)
Uric acid level, mmol/l0.40 (0.13)
Uric acid level < 0.36 mmol/l (independent of ULT), n (%)38 (46.9)
Tophaceous gout, n (%)38 (46.9)
  Tophi in foot, n (%)15 (18.5)
No. tophi, mean (median) [IQR]2.0 (0) [0–2]
RDCI (0–9), mean (median) [IQR]2.8 (3) [2–4]
Chronic kidney disease, n (%)
  MDRD < 60 ml/min/1.73 m230 (37.0)
  MDRD < 30 ml/min/1.73 m211 (13.6)
Gout-modified SvdH-score, foot
  Total (0–168), mean (median) [IQR]5.1 (4.5) [1.5–7.5]
  Erosion (0–120), mean, (median) [IQR]1.6 (0.5) [0.0–2.0]
  JSN score (0–48), mean, (median) [IQR]3.5 (3.0) [1.0–5.3]
HAQ-DI (0–3)0.65 (0.59)
SF-36 PCS (0–100)38.7 (11.9)
SF-36 MCS (0–100)49.2 (12.7)
  • RDCI: Rheumatic Disease Comorbidity Index; MDRD: Modification of Diet in Renal Disease Study equation; SvdH score: Sharp/van der Heijde score; JSN: joint space narrowing; HAQ-DI: Health Assessment Questionnaire-Disability Index; SF-36 PCS: Medical Outcomes Study Short Form-36 questionnaire physical component score; SF-36 MCS: SF-36 mental component score; IQR: interquartile range; ULT: urate-lowering therapy.